迟发性皮肤卟啉症

报告1例迟发性皮肤卟啉症.患者男,52岁.曝光部位出现红斑及水疱1年余.既往酗酒30年.皮肤科检查:面部、双手背红斑及多发色素沉着斑,左手背见花生米大水疱.皮损组织病理示表皮下水疱和毛虫小体;尿卟啉阳性;诊断为迟发性皮肤卟啉症.予保肝、戒酒及避光后皮损好转.     

迟发性皮肤卟啉症1例

1病历摘要 患者,男,67岁,头面部及双前臂手背泛发水疱、糜烂结痂2年。患者于前年开始出现头顶部及手背部瘙痒伴有水疱,搔抓后皮肤易出现水疱,皮疹恢复后遗留结痂及疤痕,皮疹反复出现并同时蔓延至面部和双前臂伸侧,自觉瘙痒剧烈,无季节性,日晒后加重。     

迟发性皮肤卟啉症1例

 报告1例迟发性皮肤卟啉症。患者男,38岁,面部色素沉着、多毛,双手背红斑、水疱、糜烂、结痂半年余。既往有饮酒史10余年,每天约3两,发现肝功能异常2年余,余系统检查未见异常。皮肤专科查体：面部多发、弥漫性褐色色素沉着斑,双侧颧部、眶周皮肤毳毛增多,双手背见大小不等红斑、水疱、糜烂、结痂,部分好转后遗留萎缩性瘢痕。皮损组织病理学示：表皮下水疱,真皮乳头血管周围见均质红染环状沉积,少量淋巴单核细胞浸润,PAS 染色示血管周围有PAS沉积,符合卟啉病皮肤改变。诊断：迟发性皮肤卟啉症。予烟酰胺片、β-胡萝卜素片口服及外用氧化锌软膏治疗后皮损好转。     

迟发性皮肤卟啉症一例

患者女,41岁。因面颈部、四肢出现皮疹伴痒1年余就诊。患者1年前无明显诱因面颈部、双手足背部皮肤呈褐色,无痒痛等自觉症状,日晒后出现散在的芝麻至黄豆大小水疱,伴瘙痒,有糜烂、结痂、脱落,留有凹陷性瘢痕。皮肤碰及硬物后易擦破。皮损反复发作,夏重冬轻,恢复缓慢。曾到当地医院就诊,诊断为多形性日光疹,治疗（药物不详）效果不明显。无明显乏力及关节酸软等症状。未留意尿液颜色有无变化,无其他全身不适。患者平素体健,无长期服药史及饮酒史。父母非近亲结婚,家族中无类似皮肤病史……     

迟发性皮肤卟啉病一例

47岁男性患者,面颈部、背部、双上肢红斑、丘疹、水疱伴瘙痒5个月余,日晒及饮酒后加重。肝功能显示转氨酶升高,尿Wood灯下呈珊瑚红色荧光。皮损组织病理：表皮下水疱形成,疱内无炎性细胞浸润,真皮下层胶原纤维增生,间有黏蛋白沉积。免疫荧光未见荧光物质沉积。全基因组外显子测序未见相关基因突变。诊断：迟发性皮肤卟啉病。给予羟氯喹、复方甘草酸苷治疗后病情缓解,随访6个月未见复发。     

迟发性皮肤卟啉病1例

患者男,51岁.面、颈、双手水疱、糜烂、瘢痕形成3个月.肝功能显示转氨酶升高,血清总卟啉水平升高,尿Wood灯下显示粉红色荧光,组织病理示:表皮下裂隙,真皮炎性反应稀疏.诊断为迟发性皮肤卟啉症(PCT).予复方甘草酸苷治疗后病情缓解.     

迟发性皮肤卟啉病1例

迟发性皮肤卟啉病（porphyria cutanea tarda，PCT）属于红细胞系疾病。其临床特点为慢性皮肤损害，起病缓慢，症状轻重不一轻者仅皮肤发红，重背出现大小不一的水疱，可以是血性的，皮肤糜烂，结痂或形成溃疡，最后形成瘢痕。笔者见到1例现报道如下。     

迟发性皮肤卟啉病1家系报告

报告一家系迟发性皮肤卟啉病。先证者女,43岁。颜面、双耳、颈部及双手背部反复出现水疱、结痂,伴瘙痒20年,日晒后即感瘙痒加重。手背组织病理示:表皮下水疱,胶原束增厚,真皮有均质性嗜伊红物质。PAS染色阳性。Wood灯下呈亮粉色荧光。诊断:迟发性皮肤卟啉病。     

迟发性皮肤卟啉病1例

迟发性皮肤卟啉病（porphyria cutanea tarda，PCT）系尿卟啉原脱羧酶的代谢缺陷所致，是最常见的卟啉病，可分为两型，一型为散发型，另一型为家族型。在临床上表现为一种光敏性皮肤病，（30～40）岁时发生水疱、大疱，多毛和色素沉着是其特征，亦称为慢性肝型卟啉病（chronic hepatic porphyria）、症状性卟啉病（symptomatic porphyria）和特应性卟啉病（idiosyneratic porphyria）^[1]。我科最近发现1例患者，经临床表现、病理和相关实验室检查确诊为迟发性皮肤卟啉病，现报告如下。     

Porphyria cutanea tarda and hematologic malignancy - a report of 4 cases

Porphyria cutanea tarda has been reported in association with a variety of myeloproliferative and lymphoproliferative disorders, suggesting a possible association between these conditions. We describe four patients presenting within a 12 month period with sporadic porphyria cutanea tarda shortly following the diagnosis of hematologic malignancy. A review of the literature and evidence supportive of a causal association are presented.     

Porphyria cutanea tarda and chronic lymphoid leukemia

A case of a familial porphyria cutanea tarda (PCT-II) is reported in which the clinically overt form of PCT was provoked by factors relating to chronic lymphoid leukemia (CLL). Typical lesions of PCT developed on a 55-year-old woman after several blood transfusions and chlorambucil treatment. Besides these provoking factors, cytomegalovirus (CMV) infection was diagnosed. Erythrocyte uroporphyrinogen decarboxylase activity was about 50% of normal in the patient and in her two children. This case supports the suggestion that development of PCT in patients with hematological disorders is more than coincidental but may in fact be provoked by exogenous factors relating to the treatment of leukemia.     

A case of porphyria cutanea tarda in association with idiopathic myelofibrosis and CREST syndrome

We report a 56-year-old Korean woman with porphyria cutanea tarda (PCT), showing multiple scarring bullae and hypertrichosis on sun-exposed areas of skin with postinflammatory hyperpigmentation. Sclerodermoid changes were also found on both hands, the face and neck. The patient had suffered from CREST syndrome, manifesting with Raynaud's phenomenon and sclerodactyly, for more than 15 years. Anticentromere antibody was positive. She had presented with splenomegaly 3 years before the development of PCT, and was diagnosed as having idiopathic myelofibrosis, based on bone marrow biopsy. In summary, she had had CREST syndrome for 15 years and later developed idiopathic myelofibrosis and PCT. This is the first reported case of PCT in association with idiopathic myelofibrosis and CREST syndrome.     

Porphyria cutanea tarda symptomatica in children treated with chloroquine. Report of four cases with control liver biopsies

Four children with porphyria cutanea tarda symptomatica were reported. Two of them had a previous history of exposure to pesticides. All four received a daily treatment of 250 mg of chloroquine for seven days. Liver function test results were altered immediately after conclusion of the therapy and porphyrin levels were very high. A light and electron microscopic examination of eight control liver biopsies revealed fatty changes before treatment, extensive liver damage during treatment, and regeneration of the liver parenchyma after the treatment. In view of the transient, but severe, liver damage, this therapeutic modality is not recommended for the treatment of children with porphyria cutanea tarda.     

Hair darkening in porphyria cutanea tarda

Repigmentation of grey hair is rare, but has been described in several clinical settings. It has most often been reported as a postinflammatory effect, but several drugs, chronic arsenic exposure and coeliac disease have also been cited in addition to darkening as a spontaneous phenomenon. We report two patients with sustained repigmentation of the hair in association with porphyria cutanea tarda. The mechanism for this repigmentation remains elusive, but presumably involves recruitment of outer root sheath melanocytes, which are then activated to form functional hair bulb melanocytes.     

The molecular basis of porphyria cutanea tarda in Chile: identification and functional characterization of mutations in the uroporphyrinogen decarboxylase gene

The porphyrias are heterogeneous disorders arising from predominantly inherited catalytic deficiencies of specific enzymes in heme biosynthesis. Porphyria cutanea tarda (PCT) results from a decreased activity of uroporphyrinogen decarboxylase, the fifth enzyme in heme biosynthesis. The disorder represents the only porphyria that is not exclusively inherited monogenetically. In PCT, at least two different types can be distinguished: acquired/sporadic (type I) PCT, in which the enzymatic deficiency is limited to the liver and inherited/familial (type II) PCT, which is inherited as an autosomal dominant trait with a decrease of enzymatic activity in all tissues. In an effort to characterize the molecular basis of PCT in Chile, we identified eight mutations in 18 previously unclassified PCT families by polymerase chain reaction, heteroduplex analysis, and automated sequencing. To study the role of these mutations in disease causality, in vitro expression of all novel missense mutations was studied. Our results indicate that the frequency of familial PCT in Chile is approximately 50%, thus, to our knowledge, representing the highest incidence of familial PCT reported to date. The data further emphasize the molecular heterogeneity in type II PCT and demonstrate the advantages of molecular genetic techniques as a diagnostic tool and in the detection of clinically asymptomatic mutation carriers.